Skip to main content

11-22-2022 | Dulaglutide | News


FDA clears dulaglutide for adolescents

Author: Eleanor McDermid


medwireNews: The FDA has approved extending use of dulaglutide to children and adolescents aged 10 years or older who have type 2 diabetes.

Treatment with the weekly injectable glucagon-like peptide-1 receptor agonist resulted in significant reductions in glycated hemoglobin levels, relative to placebo treatment, among young people aged 10–17 years in the AWARD-PEDS trial, published in June this year.

It did not significantly reduce weight, however.

Dulaglutide is also indicated to reduce glucose levels in adults with type 2 diabetes and to reduce the risk for major adverse cardiovascular events in those at high risk.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video